.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX18_Amivantamab.Amivantamab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX18_Amivantamab.Amivantamab| name: | Amivantamab |
| ATC code: | L01FX18 | route: | intravenous |
| n-compartments | 2 |
Amivantamab is a fully human bispecific monoclonal antibody targeting EGFR and MET receptors. It is used for the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations and was approved by the FDA in 2021 for this indication.
Pharmacokinetic parameters reported in adult patients with advanced non-small cell lung cancer receiving intravenous amivantamab as monotherapy.
Haddish-Berhane, N, et al., & Zhou, H (2024). Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung Cancer. Clinical pharmacology and therapeutics 115(3) 468–477. DOI:10.1002/cpt.3064 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37776107